原发性乳腺癌术前CA 15-3检测的评估
An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma.
作者信息
O'Hanlon D M, Kerin M J, Kent P, Maher D, Grimes H, Given H F
机构信息
Department of Surgery, University College Hospital, Galway, Ireland.
出版信息
Br J Cancer. 1995 Jun;71(6):1288-91. doi: 10.1038/bjc.1995.249.
Abstract
In this study of 500 patients with breast carcinoma, we have prospectively assessed the role of preoperative CA 15-3 as a marker of disease burden over a 7 year period. CA 15-3 levels at presentation correlate with stage of disease, tumour size, lymph node status, the presence of metastases and lymphocyte infiltration into the tumour. CA 15-3 alone is not an independent prognostic indicator, although a serum level of > 40 U ml-1 has a positive predictive value of 83% for the presence of advanced disease. We recommend the routine use of this marker in the preoperative assessment of primary breast carcinoma.
摘要
在这项对500例乳腺癌患者的研究中，我们前瞻性地评估了术前CA 15 - 3作为疾病负荷标志物在7年期间的作用。就诊时的CA 15 - 3水平与疾病分期、肿瘤大小、淋巴结状态、转移情况以及肿瘤内淋巴细胞浸润相关。尽管血清水平>40 U/ml对晚期疾病的存在具有83%的阳性预测价值，但单独的CA 15 - 3并非独立的预后指标。我们建议在原发性乳腺癌的术前评估中常规使用该标志物。
相似文献
1
An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma.原发性乳腺癌术前CA 15-3检测的评估
Br J Cancer. 1995 Jun;71(6):1288-91. doi: 10.1038/bjc.1995.249.
2
Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma.术前CA 15-3浓度可预测乳腺癌患者的预后。
Cancer. 1998 Dec 15;83(12):2521-7.
3
4
Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.局部区域性乳腺癌患者癌胚抗原（CEA）和糖类抗原15.3（CA 15.3）的前瞻性评估
Anticancer Res. 2003 Mar-Apr;23(2A):1035-41.
5
Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.前哨淋巴结作为乳腺癌患者治疗规划的新标志物。
J Surg Oncol. 2004 Mar;85(3):102-11. doi: 10.1002/jso.20022.
6
Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer.癌胚抗原（CEA）和糖类抗原15-3（CA 15-3）在浸润性乳腺癌随访中的预测价值。
Anticancer Res. 1999 Jul-Aug;19(4A):2567-70.
7
Serum level of angiogenin in breast cancer.
Anticancer Res. 2000 Nov-Dec;20(6C):4769-71.
8
[Clinical and prognostic significance of preoperative serum CA153, CEA and TPS levels in patients with primary breast cancer].[原发性乳腺癌患者术前血清CA153、CEA及TPS水平的临床及预后意义]
Zhonghua Zhong Liu Za Zhi. 2011 Nov;33(11):842-6.
9
Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game.血清CA15.3在362例淋巴结阴性乳腺癌中的预后作用。老指标用于新研究。
Eur J Cancer. 2002 Jun;38(9):1181-8. doi: 10.1016/s0959-8049(01)00426-9.
10
Plasma TuM2-PK correlates with tumor size, CRP and CA 15-3 in metastatic breast carcinomas; short versus long term follow up study of the Egyptian breast cancer patients.转移性乳腺癌中血浆TuM2-PK与肿瘤大小、CRP及CA 15-3的相关性；埃及乳腺癌患者的短期与长期随访研究
Cancer Biomark. 2017 Aug 23;20(2):123-133. doi: 10.3233/CBM-160482.
引用本文的文献
1
Detection of IL-1β, VEGF and IL-4 with their novel genetic variations in breast cancer patients.检测乳腺癌患者中白细胞介素-1β、血管内皮生长因子和白细胞介素-4及其新的基因变异。
Saudi J Biol Sci. 2023 Feb;30(2):103544. doi: 10.1016/j.sjbs.2022.103544. Epub 2022 Dec 23.
2
Discovering Breast Cancer Biomarkers Candidates through mRNA Expression Analysis Based on The Cancer Genome Atlas Database.基于癌症基因组图谱数据库通过mRNA表达分析发现乳腺癌生物标志物候选物。
J Pers Med. 2022 Oct 21;12(10):1753. doi: 10.3390/jpm12101753.
3
Identification of Flap Endonuclease 1 With Diagnostic and Prognostic Value in Breast Cancer.鉴定具有乳腺癌诊断和预后价值的瓣内切核酸酶1
Front Oncol. 2021 Jun 30;11:603114. doi: 10.3389/fonc.2021.603114. eCollection 2021.
4
The diagnostic power of circulating micro ribonucleic acid 34a in combination with cancer antigen 15-3 as a potential biomarker of breast cancer.循环微小核糖核酸34a联合癌抗原15-3作为乳腺癌潜在生物标志物的诊断效能
Saudi Med J. 2019 Dec;40(12):1218-1226. doi: 10.15537/smj.2019.12.24712.
5
Label-Free Flow Multiplex Biosensing via Photonic Crystal Surface Mode Detection.基于光子晶体表面模式检测的无标记流动多元生物传感
Sci Rep. 2019 Jun 19;9(1):8745. doi: 10.1038/s41598-019-45166-3.
6
Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers.预测早期乳腺癌新辅助治疗的反应：肿瘤、血液和影像学相关生物标志物。
Cancer Manag Res. 2018 Oct 9;10:4333-4347. doi: 10.2147/CMAR.S174435. eCollection 2018.
7
Autoantibodies as Potential Biomarkers in Breast Cancer.自身抗体作为乳腺癌潜在的生物标志物。
Biosensors (Basel). 2018 Jul 13;8(3):67. doi: 10.3390/bios8030067.
8
Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA.通过联合miR-34a与肿瘤标志物CA 15-3或癌胚抗原（CEA）提高乳腺癌检测的灵敏度。
Oncotarget. 2018 Apr 27;9(32):22523-22536. doi: 10.18632/oncotarget.25077.
9
The Role of F-FDG PET/CT in Evaluating Elevated Levels of Tumor Markers in Breast Cancer.F-FDG PET/CT在评估乳腺癌肿瘤标志物水平升高中的作用
Mol Imaging Radionucl Ther. 2018 Feb 1;27(1):3-9. doi: 10.4274/mirt.74436.
10
The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis.微小RNA-34a在乳腺癌中的诊断作用：一项系统评价与Meta分析
Oncotarget. 2017 Apr 4;8(14):23177-23187. doi: 10.18632/oncotarget.15520.
本文引用的文献
1
Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.乳腺癌的组织学分级与预后；对1409例病例的研究，其中359例已随访15年。
Br J Cancer. 1957 Sep;11(3):359-77. doi: 10.1038/bjc.1957.43.
2
Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors.抗人乳脂肪球膜的单克隆抗体可检测乳腺及其肿瘤的分化抗原。
Int J Cancer. 1984 Aug 15;34(2):197-206. doi: 10.1002/ijc.2910340210.
3
Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors.一种新型单克隆抗体（DF3）对人类恶性与良性乳腺肿瘤的不同反应性。
Hybridoma. 1984 Fall;3(3):223-32. doi: 10.1089/hyb.1984.3.223.
4
Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients.使用鼠单克隆抗体检测乳腺癌患者循环血浆DF3抗原水平。
J Clin Invest. 1985 May;75(5):1671-8. doi: 10.1172/JCI111875.
5
MAM-6 antigen, a new serum marker for breast cancer monitoring.
Cancer Res. 1986 May;46(5):2582-7.
6
CA 15.3 as a tumour marker in breast cancer.CA 15.3作为乳腺癌的肿瘤标志物。
Int J Biol Markers. 1987 Sep-Dec;2(3):135-42. doi: 10.1177/172460088700200301.
7
Value of CA 15:3 in the follow-up of breast cancer patients.CA 15:3在乳腺癌患者随访中的价值。
Br J Cancer. 1987 May;55(5):567-9. doi: 10.1038/bjc.1987.115.
8
CA15-3: its relationship to clinical stage and progression to metastatic disease in breast cancer.CA15 - 3：其与乳腺癌临床分期及转移至转移性疾病进展的关系。
Br J Surg. 1989 Aug;76(8):838-9. doi: 10.1002/bjs.1800760826.
9
Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.乳腺癌患者循环CA15-3和癌胚抗原水平的比较。
J Clin Oncol. 1986 Oct;4(10):1542-50. doi: 10.1200/JCO.1986.4.10.1542.
10
Assessment of four monoclonal antibodies as serum markers in breast cancer.评估四种单克隆抗体作为乳腺癌血清标志物的情况。
Eur J Cancer. 1990;26(11-12):1127-32. doi: 10.1016/0277-5379(90)90268-x.
Zotero 插件